How much have AI applications learned, and how can one know their capabilities if they are being evaluated with an exam that is far too easy? In 2024, with the publication of the previous benchmark to measure AI performance, the field debated whether existing assessments would keep pace with the rapid progress of AI. Read More
Bone metastasis represents a challenge in cancer therapy because of the independency of immunosuppression, neuropathic pain and osteolytic destruction. Recent evidence has suggested the tumor microenvironment can be reshaped through the activation of stimulator of interferon genes protein (STING) and pyroptosis induction. Read More
Insilico Medicine Cayman Topco has nominated ISM-0676 as a preclinical candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). Read More
Formation Bio Inc. and Jiangsu Chia Tai Feng Hai Pharmaceutical Co. Ltd. have announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to FHND-5032, an oral, small-molecule miR-124 activator being developed for the treatment of autoimmune diseases. Read More
DFNB16, a recessive form of mild-to-moderate human deafness, is caused by mutations in the STRC gene, which encodes stereocilin, a protein essential for the effective function of outer hair cells as cochlear amplifiers. Researchers from the Institut Pasteur and Sorbonne Université in Paris, France, have developed and evaluated the efficacy of an Strc gene therapy in a mouse model of DFNB16. Read More
Ahead Therapeutics SL has been awarded an Industry Discovery and Development Partnership (IDDP) grant from Breakthrough T1D to support progression of the company’s proprietary Mimi-Top (mimicking tolerogenic particles) platform. Read More
Humanwell Pharmaceutical US Inc. has disclosed prodrugs of somatostatin SST4 receptor agonists described as potentially useful for the treatment of visceral and neuropathic pain. Read More
Astrazeneca plc has signed a new strategic collaboration agreement with CSPC Pharmaceutical Group Ltd. to advance the development of next-generation therapies for obesity and type 2 diabetes across eight programs. Read More
Terns Pharmaceuticals Inc. has reported triazole compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. They are intended for use in the treatment of diabetes, obesity, liver diseases and cardiometabolic syndrome. Read More
In a recent paper, researchers from the University of Perugia and University of Naples Federico II have shown how the use of leukemia inhibitory factor receptor (LIFR) antagonists dismantles the pro-CAF programs in pancreatic ductal adenocarcinoma (PDAC) to avoid its progression. Read More
University of Florida researchers have synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)- and apoptosis regulator Bcl-2-targeting moiety. Read More
Asieris Pharmaceuticals (USA) Inc. has discovered new antibody-drug conjugates comprising antibodies covalently linked to payloads through linkers. Read More
To address the dual bottlenecks of immunosuppressive cell infiltration and impaired T-cell function in the tumor microenvironment (TME), researchers from the School of Pharmaceutical Sciences of Sun Yat-sen University (China) aimed to develop an engineered bispecific peptide-nanozyme conjugate (BsPNEC) targeting PD-L1 and CXCR1/2. Read More
